These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34276440)

  • 1. Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial.
    Johns SE; Keyser-Marcus L; Abbate A; Boone E; Van Tassell B; Cunningham KA; Anastasio NC; Poklis JL; Ramey T; Moeller FG
    Front Psychiatry; 2021; 12():666945. PubMed ID: 34276440
    [No Abstract]   [Full Text] [Related]  

  • 2. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.
    Pirtle JL; Hickman MD; Boinpelly VC; Surineni K; Thakur HK; Grasing KW
    Pharmacol Biochem Behav; 2019 May; 180():52-59. PubMed ID: 30811963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial.
    Santos GM; Ikeda J; Coffin P; Walker JE; Matheson T; McLaughlin M; Jain J; Vittinghoff E; Batki SL
    PLoS One; 2021; 16(7):e0254724. PubMed ID: 34265007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder.
    McCann DJ; Chen HH; Devine EG; Gyaw S; Ramey T
    Drug Alcohol Depend; 2024 Feb; 255():111063. PubMed ID: 38163425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.
    Brandt L; Jones JD; Martinez S; Manubay JM; Mogali S; Ramey T; Levin FR; Comer SD
    Drug Alcohol Depend; 2020 Mar; 208():107859. PubMed ID: 31980285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated 7-Day Treatment with the 5-HT
    Banks ML; Negus SS
    Neuropsychopharmacology; 2017 Apr; 42(5):1082-1092. PubMed ID: 27857126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys.
    Collins GT; Gerak LR; Javors MA; France CP
    J Pharmacol Exp Ther; 2016 Jan; 356(1):85-95. PubMed ID: 26534942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
    Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-HT
    Campbell EJ; Bonomo Y; Pastor A; Collins L; Norman A; Galettis P; Johnstone J; Lawrence AJ
    Pharmacol Res Perspect; 2021 May; 9(3):e00767. PubMed ID: 33929084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 5-HT(2C) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity.
    Harvey-Lewis C; Li Z; Higgins GA; Fletcher PJ
    Neuropharmacology; 2016 Feb; 101():237-45. PubMed ID: 26427596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.
    Arout CA; Cooper ZD; Reed SC; Foltin RW; Comer SD; Levin FR; Haney M
    Addict Biol; 2021 Jul; 26(4):e12993. PubMed ID: 33389797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys.
    Collins GT; France CP
    Exp Clin Psychopharmacol; 2018 Oct; 26(5):488-496. PubMed ID: 29952618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
    Shram MJ; Schoedel KA; Bartlett C; Shazer RL; Anderson CM; Sellers EM
    Clin Pharmacol Ther; 2011 May; 89(5):683-92. PubMed ID: 21412231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Lorcaserin on Cocaine and Methamphetamine Self-Administration and Reinstatement of Responding Previously Maintained by Cocaine in Rhesus Monkeys.
    Gerak LR; Collins GT; France CP
    J Pharmacol Exp Ther; 2016 Dec; 359(3):383-391. PubMed ID: 27650954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
    Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR;
    Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incubation of cocaine cue reactivity associates with neuroadaptations in the cortical serotonin (5-HT) 5-HT2C receptor (5-HT2CR) system.
    Swinford-Jackson SE; Anastasio NC; Fox RG; Stutz SJ; Cunningham KA
    Neuroscience; 2016 Jun; 324():50-61. PubMed ID: 26926963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
    Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    Bohula EA; Wiviott SD; McGuire DK; Inzucchi SE; Kuder J; Im K; Fanola CL; Qamar A; Brown C; Budaj A; Garcia-Castillo A; Gupta M; Leiter LA; Weissman NJ; White HD; Patel T; Francis B; Miao W; Perdomo C; Dhadda S; Bonaca MP; Ruff CT; Keech AC; Smith SR; Sabatine MS; Scirica BM;
    N Engl J Med; 2018 Sep; 379(12):1107-1117. PubMed ID: 30145941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metyrapone and cocaine: a double-blind, placebo-controlled drug interaction study.
    Winhusen T; Somoza E; Harrer JM; Moore E; Ussery T; Kropp F; Singal B; Elkashef A; Mojsiak J
    Pharmacol Biochem Behav; 2005 Apr; 80(4):631-8. PubMed ID: 15820533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.